Australia's Mayne Pharma soars 13% on strong first-half earnings forecast

Mayne Pharma

09/02/2025 23:43

** Shares of Mayne Pharma Group  MYX.AX  soar 13.3% to
A$5.30, their highest level since December 3, 2024
    ** Stock heads for a fourth consecutive session of gains,
among top gainers in the ASX All Ordinaries index  .AORD 
    ** Speciality pharmaceutical firm says it expects 1H25
underlying EBITDA between A$30 million ($18.76 million) and A$32
million, up to four-fold jump from last year's A$8 million
    ** Revenue forecast between A$210 million and A$215 million,
up to 14% growth
    ** Co expects to see continued growth in 2H25
    ** More than 112,000 shares change hands, vs the 30-day
average of about 95,000 shares
    ** MYX up 6.8% this year, including day's moves

($1 = 1.5995 Australian dollars)

 (Reporting by Sameer Manekar in Bengaluru)
 ((Sameer.Manekar@thomsonreuters.com;))